Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01648205
Other study ID # IN-US-259-0128
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2012
Est. completion date July 20, 2018

Study information

Verified date March 2022
Source University of Rochester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether late sodium channel blockade might be effective in shortening the QTc interval in various LQT3 mutations and be considered as a safe therapeutic option for LQT3 patients.


Description:

Long QT syndrome (LQTS) is a genetic disorder characterized by prolongation of the QT interval in the electrocardiogram (ECG) and a propensity to torsade de pointes ventricular tachycardia frequently leading to syncope, cardiac arrest, or sudden death usually in young otherwise healthy individuals. The long QT syndrome is caused by mutations of predominantly potassium and sodium ion channel genes or channel-related proteins. The most common types of LQTS affect: the slow delayed rectifier potassium repolarization channel (KCNQ1; LQT1) resulting in a reduction in IKs current; the rapid delayed rectifying potassium repolarization channel (KCNH2; LQT2) resulting in a reduction in IKr current; and the sodium channel (SCN5A; LQT3) resulting in an increase in late INa current. Among positively genotyped patients, LQT1 and LQT2 account for about 90% of LQTS cases, whereas LQT3 accounts for about 5% to 8% of cases. LQT3 patients represent a challenging cohort of patients. Unlike patients with LQT1 and LQT2 form of this disorder, the LQT3 patients have high lethality of cardiac events with 1 in 5 patients dying suddenly during their first syncopal or arrhythmic event. In childhood (age 0-18) in the analysis of 1,404 patients, LQT3 was found to be associated with significantly higher risk of aborted cardiac arrest or death than LQT1 and LQT2. A similar pattern is observed in LQTS patients after age 40 in whom LQT3 patients show the highest risk. Optimal therapy in LQT3 patients remains controversial. There are data showing that sodium current blockers including mexiletine and flecainide shorten QTc duration in LQT3 patients. Ranolazine is a selective late sodium current inhibitor that has been also showed to reduce QTc in DKPQ mutation and D1790G mutation patients. However, data on long-term effectiveness of ranolazine are limited. This single-blinded study evaluated a long-term effects of ranolazine on QTc duration in LQT3 patients with various LQT3 mutations. Enrolled subjects are treated for 1 months with matching placebo and next for subsequent 5 months with ranolazine with ECG recorded at baseline, 1 , 2, and 6 months of follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date July 20, 2018
Est. primary completion date July 20, 2018
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Genotyped positive for LQT3 (SCN5A) mutation - Age 21 years or older - Not currently taking an antiarrhythmic drug (beta blockers are allowed) - Enrolled in LQTS Registry Exclusion Criteria: - Age less than 21 years - Not confirmed to have an LQT3 mutation - Significant co-morbidity that would preclude subject's safe participation in this study - Females who are pregnant or nursing - Females of childbearing age who are not using acceptable method of birth control - Evidence of prior sensitivity to ranolazine - Hepatic or renal disease that might adversely affect ranolazine excretion - Currently taking strong CYP3A inhibitors - Currently taking P-gp inhibitors - Currently taking CYP3A inducers - In vitro studies of specific mutation show no effect of ranolazine on late sodium current kinetics or show repolarization prolongation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Matching Placebo will be given for first month.
Ranolazine
Patients will receive ranolazine 1000mg bid for subsequent 5 months.

Locations

Country Name City State
United States University of Rochester Rochester New York

Sponsors (2)

Lead Sponsor Collaborator
University of Rochester Gilead Sciences

Country where clinical trial is conducted

United States, 

References & Publications (5)

Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I, Medina A. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation. 2000 Apr 11;101(14):1698-706. — View Citation

Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008 Dec;19(12):1289-93. doi: 10.1111/j.1540-8167.2008.01246.x. Epub 2008 Jul 25. — View Citation

Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantù F, Towbin JA, Keating MT, Hammoude H, Brown AM, Chen LS, Colatsky TJ. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995 Dec 15;92(12):3381-6. — View Citation

Zareba W, Moss AJ, Locati EH, Lehmann MH, Peterson DR, Hall WJ, Schwartz PJ, Vincent GM, Priori SG, Benhorin J, Towbin JA, Robinson JL, Andrews ML, Napolitano C, Timothy K, Zhang L, Medina A; International Long QT Syndrome Registry. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol. 2003 Jul 2;42(1):103-9. — View Citation

Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ. Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med. 1998 Oct 1;339(14):960-5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in QTc Duration at 2 Months Change in QTc at 2 months on ranolazine vs. at 1 month on placebo. This was prespecified outcome. 1 month to 2 months
Secondary Change in QTc at 6 Months Change in QTc at 6 months on ranolazine vs. at 1 month on placebo. This was prespecified outcome. 1 month to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4
Recruiting NCT06087367 - Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects
Recruiting NCT04675788 - Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening Phase 4
Completed NCT05759962 - Phase 1 Study of LQT-1213 in Healthy Adults Phase 1
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Terminated NCT02439645 - A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
Recruiting NCT00221832 - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases N/A
Completed NCT04706104 - QT Measurement Techniques and Anesthesia Management
Recruiting NCT04336644 - Continuous Versus Intermittent cARdiac Electrical moNitorinG N/A
Recruiting NCT02814981 - Hydroxyzine and Risk of Prolongation of QT Interval N/A
Completed NCT02876380 - Prospective Identification of Long QT Syndrome in Fetal Life
Completed NCT02425189 - The Canadian National Long QT Syndrome Registry
Completed NCT00399412 - ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients N/A
Completed NCT02513940 - Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes Phase 4
Completed NCT03182777 - Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies N/A
Completed NCT02441829 - Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function Phase 1
Completed NCT01849003 - Study of the Effect of GS-6615 in Subjects With LQT-3 Phase 1
Completed NCT00316459 - Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects Phase 1
Completed NCT00292032 - Registry of Unexplained Cardiac Arrest
Recruiting NCT05348564 - Comparing Direct vs Indirect Methods for Cascade Screening N/A